What Genmab’s latest trial data and royalty update mean for shareholders Genmab (CPSE:GMAB) has drawn fresh attention after releasing Phase 3 EPCORE DLBCL-1 topline data for epcoritamab and reporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results